BillionToOne joined the Unicorn Club after raising $130M in a Series D funding round led by Premji Invest, reaching a $1B valuation. The San Francisco-based genomics company develops cell-free liquid biopsy tests for cancer detection and precision diagnostics. Its proprietary molecular counter platform quantifies DNA molecules from blood samples, supporting advanced genetic testing and early disease detection.
Keep reading to explore BillionToOne’s funding history, key investors, and what’s next for this genomics and oncology innovator.
What Is BillionToOne and What Does It Do?
Founded in 2015, BillionToOne is headquartered in San Francisco, California, United States. The company provides molecular diagnostic solutions that leverage its proprietary molecular counter platform to count DNA molecules from blood samples accurately. Its tests cover conditions such as cystic fibrosis, spinal muscular atrophy, and sickle cell disease, as well as oncology-focused liquid biopsy diagnostics.
BillionToOne’s mission is to make high-accuracy molecular testing more accessible and affordable for global healthcare systems.
How Much Funding Has BillionToOne Raised?
- Series D
- Amount Raised: $130M
- Date: June 21, 2024
- Lead Investors: Premji Invest
- Motivation: Expand oncology testing portfolio, accelerate clinical adoption, and scale diagnostic operations globally.
Total Funding Raised: $389M
Latest Funding Date: June 21, 2024
Key Investors
- Baillie Gifford
- Details: Global investment management firm investing in high-growth technology and healthcare companies.
- Investment Focus Areas: Genomics, biotechnology, and medical innovation.
- Notable Investments: Healthcare startups focused on advanced diagnostics and precision medicine.
- Premji Invest
- Details: Private equity and venture capital firm backed by Wipro founder Azim Premji.
- Investment Focus Areas: Healthcare, technology, and consumer sectors.
- Notable Investments: High-impact healthcare and life sciences companies.
Where Is BillionToOne’s Headquarters?
BillionToOne is headquartered in San Francisco, California, United States, providing access to leading biotech talent and proximity to primary healthcare and research ecosystems.
What’s Next for BillionToOne?
BillionToOne aims to accelerate the adoption of its cell-free cancer liquid biopsy tests and expand its molecular diagnostics portfolio. Backed by $389 million in total Funding and a $1 billion valuation, the company plans to enhance the accessibility of precision medicine, scale its clinical operations, and strengthen its position in the global genomics and oncology markets.
Get Investor & Funding Insights with TexAu
TexAu provides detailed fundraising data on companies like BillionToOne. Track investors, monitor funding rounds, and gather actionable insights to strengthen your sales and business strategy.
Sign up for Free on TexAu and turn data into smarter, faster business decisions.
